PCVX (Vaxcyte) OCF Margin %: 0.00% (As of Mar. 2026)


PCVX Vaxcyte Inc PCVX
34 GF Score
Price $56.52
! 2 Warning Signs
View Full Analysis

What is Vaxcyte OCF Margin %?

Vaxcyte PCVX +5.23% 34 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates PCVX with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Vaxcyte ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Vaxcyte's Cash Flow from Operations for the three months ended in Mar. 2026 was $-280.63 Mil. Vaxcyte's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Vaxcyte's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Vaxcyte's current OCF Yield % is -9.43%.

The historical rank and industry rank for Vaxcyte's OCF Margin % or its related term are showing as below:


PCVX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Vaxcyte OCF Margin % Related Terms

Vaxcyte OCF Margin % Historical Data

* Premium members only.

The historical data trend for Vaxcyte's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxcyte OCF Margin % Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vaxcyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
PCVX
34GF Score
Vaxcyte Inc PCVX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxcyte OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Vaxcyte's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-655.577/0
= %

Vaxcyte's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-280.625/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Vaxcyte (PCVX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vaxcyte and its competitors. According to the industry distribution chart, Vaxcyte ranks #999999 out of 959 companies in the Biotechnology industry.
Is Vaxcyte's OCF Margin % too high?
Vaxcyte's current OCF Margin % is 0.00%. Based on the distribution chart, Vaxcyte ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vaxcyte has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Vaxcyte's OCF Margin % compare to CORT and IBRX?
According to the Biotechnology industry distribution chart, Vaxcyte ranks #999999 out of 959 companies for OCF Margin %. This places Vaxcyte in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Vaxcyte and its competitors. Vaxcyte's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxcyte stock overvalued right now?
Vaxcyte (PCVX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Vaxcyte's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Vaxcyte (PCVX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxcyte Business Description

Other Exchanges 1PCVX:Italy5VA:Germany
Address 825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
34GF Score

Get the complete analysis for PCVX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.52
Price